CN102293738A - External preparation for and method treating arthritis - Google Patents
External preparation for and method treating arthritis Download PDFInfo
- Publication number
- CN102293738A CN102293738A CN 201110228043 CN201110228043A CN102293738A CN 102293738 A CN102293738 A CN 102293738A CN 201110228043 CN201110228043 CN 201110228043 CN 201110228043 A CN201110228043 A CN 201110228043A CN 102293738 A CN102293738 A CN 102293738A
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- sulfate
- arthritis
- substrate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 21
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 21
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 claims abstract description 20
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000758 substrate Substances 0.000 claims abstract description 20
- 239000002674 ointment Substances 0.000 claims abstract description 10
- 239000007921 spray Substances 0.000 claims abstract description 10
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims description 17
- 230000002917 arthritic effect Effects 0.000 claims description 5
- 210000001503 joint Anatomy 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 201000005043 chondromalacia Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an external preparation for treating arthritis, which comprises the following components in parts by weight: 2-10 parts of chondroitin sulfate, 2-5 parts of transdermal agent, 50-80 parts of substrate and 5-10 parts of D-glucosamine hydrochloride and/or D-glucosamine sulfate. The chondroitin sulfate, transdermal agent, substrate, and D-glucosamine hydrochloride and/or D-glucosamine sulfate are processed into an ointment or spray. The invention also discloses a method for treating arthritis, which comprises the following steps: combining the chondroitin sulfate, transdermal agent, substrate, and D-glucosamine hydrochloride and/or D-glucosamine sulfate, and plastering or spraying on the joint suffering from arthritis. The invention has the advantages of obvious curative effect, high absorption speed and no toxic or side effect.
Description
Technical field
The present invention relates to a kind of external preparation of treatment of arthritis and the method for treatment of arthritis.
Background technology
Arthritis is a kind of common osteoarticular retrograde affection, falls ill usually in person in middle and old age colony, is one of major reason of disabling of middle-aged and elderly people, and social harm is very big.
If the drug main salicylic acid medicine of present treatment of arthritis, its effect also only limits to respite patient's pain symptom, treatment of arthritis fundamentally, simultaneously, the toxic and side effects of salicylic acid medicine is big, life-time service meeting grievous injury patient's liver, hemopoietic system and gastro-intestinal digestion system.
Summary of the invention
The problem to be solved in the present invention is: provide a kind of and have no side effect, infiltration rate is fast and the external preparation of the significant treatment of arthritis of effect.
In order to solve the problems of the technologies described above, the external preparation of treatment of arthritis of the present invention comprises the following component according to the ratio of weight and number meter:
Chondroitin sulfate 2-10 part;
Transdermal agent 2-5 part;
Substrate 50-80 part;
D-glucosamine hydrochlorate and/or D-glucosamine sulfate 5-10 part.
Further, the external preparation of treatment of arthritis of the present invention comprises the following component according to the ratio of weight and number meter:
Chondroitin sulfate 5-10 part;
Transdermal agent 3-5 part;
Substrate 60-75 part;
D-glucosamine hydrochlorate and/or D-glucosamine sulfate 6-8 part.
In order to accelerate the absorption of patient to medicine, the external preparation of treatment of arthritis of the present invention, described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are in conjunction with being processed into unguentum or spray.
The present invention also provides a kind of method of treatment of arthritis, and chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are combined, and smears or is sprayed at and suffer from arthritic joint.
Further, the method for treatment of arthritis of the present invention, the ratio of weight and number of described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate is 2-10 part: 2-5 part: 50-80 part: 5-10 part.
Further, the method for treatment of arthritis of the present invention, the ratio of weight and number of described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate is 2-10 part: 2-5 part: 50-80 part: 5-10 part.
Further, the method for treatment of arthritis of the present invention, described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are in conjunction with being processed into unguentum or spray.
The beneficial effect that the present invention obtains is: chondroitin sulfate has the effect of activating human body connective tissue and cell, maintenance and reparation cartilaginous tissue and prevention articular cartilage degeneration; D-glucosamine hydrochlorate and D-glucosamine sulfate have and expedite the emergence of joint lubrication liquid, repair the articular cartilage be worn and remove the harmful enzyme effect of intraarticular; Transdermal agent can promote the principal agent in the pharmaceutical preparation to penetrate in the skin sooner or more or see through the effect that skin enters blood circulation; Thereby evident in efficacy, infiltration rate is fast and have no side effect.
For therapeutic effect of the present invention is described, the spy provides following medical history information:
Lee, the man, 50 years old, lumbar vertebra cervical vertebra swelling pain was sat the difficulty that crouches, and uses unguentum of the present invention 30 days, uses every day 3 times, massages 3-5 minute at every turn, and existing swelling pain disappears, and can normally sit for sleeping in.
The Wang, the man, 38 years old, shoulder arthralgia swelling, arm can not lift, and uses spray of the present invention 50 days, sprays every day 4 times, and existing pain and swelling disappears, and arm can freely lift, and can mention 10 kilograms of weights.
Zhang, the woman, 42 years old, brothers' arthralgia, inconvenient activity was used unguentum of the present invention 20 days, used every day 3 times, and existing brothers joint is pain no longer, and can be free movable.
Dong, 62 years old, suffer from chondromalacia patella and rheumatic arthritis, arthralgia, the difficulty that crouches is sat in walking, uses spray of the present invention 60 days, and every day 5 times, existing pain condition alleviates, and can normally walk to sit and crouch.
The specific embodiment
Embodiment 1
The external preparation of the treatment of arthritis of present embodiment comprises the following component according to the ratio of weight and number meter: 5 parts of chondroitin sulfate; 3 parts of transdermal agents; 60 parts of substrate; 5 parts in D-glucosamine hydrochlorate and D-glucosamine sulfate.In the time of concrete the use, said components in conjunction with making unguentum, is applied in and suffers from arthritic joint and get final product.
Embodiment 2
The external preparation of the treatment of arthritis of present embodiment comprises the following component according to the ratio of weight and number meter: 6 parts of chondroitin sulfate; 4 parts of transdermal agents; 65 parts of substrate; 6 parts of D-glucosamine hydrochlorates.In the time of concrete the use, said components in conjunction with making spray, is sprayed at and suffers from arthritic joint and get final product.
Embodiment 3
The external preparation of the treatment of arthritis of present embodiment comprises the following component according to the ratio of weight and number meter: 8 parts of chondroitin sulfate; 3 parts of transdermal agents; 70 parts of substrate; 8 parts in D-glucosamine sulfate.In the time of concrete the use, said components in conjunction with making unguentum, is applied in and suffers from arthritic joint and get final product.
In the above-mentioned embodiment, after smearing unguentum or spraying spray, can massage, reach the effect of fast Absorption medicine to accelerate blood circulation, thereby further improve therapeutic effect, avoid the waste of medicine joint.
Claims (7)
1. the external preparation of a treatment of arthritis is characterized in that: comprise the following component according to the ratio of weight and number meter:
Chondroitin sulfate 2-10 part;
Transdermal agent 2-5 part;
Substrate 50-80 part;
D-glucosamine hydrochlorate and/or D-glucosamine sulfate 5-10 part.
2. the external preparation of treatment of arthritis according to claim 1 is characterized in that: comprise the following component according to the ratio of weight and number meter:
Chondroitin sulfate 5-10 part;
Transdermal agent 3-5 part;
Substrate 60-75 part;
D-glucosamine hydrochlorate and/or D-glucosamine sulfate 6-8 part.
3. the external preparation of treatment of arthritis according to claim 1 and 2 is characterized in that: described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are in conjunction with being processed into unguentum or spray.
4. the method for a treatment of arthritis is characterized in that: chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are combined, smear or be sprayed at and suffer from arthritic joint.
5. the method for treatment of arthritis according to claim 4, it is characterized in that: the ratio of weight and number of described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate is 2-10 part: 2-5 part: 50-80 part: 5-10 part.
6. the method for treatment of arthritis according to claim 4, it is characterized in that: the ratio of weight and number of described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate is 2-10 part: 2-5 part: 50-80 part: 5-10 part.
7. according to the method for the described treatment of arthritis of claim 4-6, it is characterized in that: described chondroitin sulfate, transdermal agent, substrate, D-glucosamine hydrochlorate and/or D-glucosamine sulfate are in conjunction with being processed into unguentum or spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110228043 CN102293738A (en) | 2011-08-10 | 2011-08-10 | External preparation for and method treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110228043 CN102293738A (en) | 2011-08-10 | 2011-08-10 | External preparation for and method treating arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102293738A true CN102293738A (en) | 2011-12-28 |
Family
ID=45354579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110228043 Pending CN102293738A (en) | 2011-08-10 | 2011-08-10 | External preparation for and method treating arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102293738A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670657A (en) * | 2012-06-01 | 2012-09-19 | 山东卫康生物医药科技有限公司 | Percutaneous absorption preparation for treating bone joint disease |
| US20170014462A1 (en) * | 2015-07-14 | 2017-01-19 | Infinitus (China) Company Ltd. | Bone and joint protection composition and use thereof |
| CN107362177A (en) * | 2017-09-07 | 2017-11-21 | 威海盛朗生物科技有限公司 | Drug component, ointment and plaster for treatment of arthritis |
| CN109568267A (en) * | 2018-12-28 | 2019-04-05 | 中山市天图精细化工有限公司 | A kind of frost pain-stopping aerosol and preparation method thereof |
| CN110548003A (en) * | 2019-10-18 | 2019-12-10 | 吉林大学 | Externally applied chondroitin sulfate nano composition as well as preparation method and application thereof |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
| CN1439313A (en) * | 2003-04-02 | 2003-09-03 | 李安虎 | Joint healthy beverage or food and preparation thereof |
| US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
| CN1562073A (en) * | 2003-05-07 | 2005-01-12 | 汤毅 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
| CN1682755A (en) * | 2004-04-16 | 2005-10-19 | 王晓 | Material for treating inflammation and pain |
| CN1771986A (en) * | 2005-10-28 | 2006-05-17 | 凌沛学 | Orally taken joint function protectant |
-
2011
- 2011-08-10 CN CN 201110228043 patent/CN102293738A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| CN1364464A (en) * | 2002-01-29 | 2002-08-21 | 郑刚 | Aminoglucose hydrochloride medicinal composition |
| US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
| CN1439313A (en) * | 2003-04-02 | 2003-09-03 | 李安虎 | Joint healthy beverage or food and preparation thereof |
| CN1562073A (en) * | 2003-05-07 | 2005-01-12 | 汤毅 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
| CN1682755A (en) * | 2004-04-16 | 2005-10-19 | 王晓 | Material for treating inflammation and pain |
| CN1771986A (en) * | 2005-10-28 | 2006-05-17 | 凌沛学 | Orally taken joint function protectant |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670657A (en) * | 2012-06-01 | 2012-09-19 | 山东卫康生物医药科技有限公司 | Percutaneous absorption preparation for treating bone joint disease |
| US20170014462A1 (en) * | 2015-07-14 | 2017-01-19 | Infinitus (China) Company Ltd. | Bone and joint protection composition and use thereof |
| US10426807B2 (en) * | 2015-07-14 | 2019-10-01 | Infinitus (China) Company Ltd. | Bone and joint protection composition and use thereof |
| CN107362177A (en) * | 2017-09-07 | 2017-11-21 | 威海盛朗生物科技有限公司 | Drug component, ointment and plaster for treatment of arthritis |
| CN109568267A (en) * | 2018-12-28 | 2019-04-05 | 中山市天图精细化工有限公司 | A kind of frost pain-stopping aerosol and preparation method thereof |
| CN109568267B (en) * | 2018-12-28 | 2021-01-05 | 中山市天图精细化工有限公司 | A kind of frozen analgesic aerosol and preparation method thereof |
| CN110548003A (en) * | 2019-10-18 | 2019-12-10 | 吉林大学 | Externally applied chondroitin sulfate nano composition as well as preparation method and application thereof |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102293738A (en) | External preparation for and method treating arthritis | |
| CN102223889A (en) | Homeopathic treatments | |
| CN101757117A (en) | Chinese herb medicine conditioner and preparation method thereof | |
| CN101721474A (en) | Externally-applied liniment for treating psoriasis | |
| CN104367738A (en) | Cell-energy skin-care liquid | |
| CN102178748B (en) | External medicament for treating ulcer | |
| CN101313940A (en) | Traditional Chinese medicine nourishing skin-protection plaster | |
| EP3369428A1 (en) | External traditional chinese medicine preparation for diminishing inflammation, relieving pain and promoting fast healing, and preparation method therefor | |
| CN1634088A (en) | Novel method for externally applied glucosamine for the treatment of arthritis and externally applied formulation of glucosamine | |
| CN100531781C (en) | A traditional Chinese medicine composition for removing warts and moles | |
| CN107510820A (en) | A kind of Chinese medicine composition for treating neck-shoulder pain, lumbago and leg pain and preparation method thereof | |
| CN102847030A (en) | Freckle-removal facial mask | |
| CN103585334B (en) | Compound diaper ointment | |
| CN102028922B (en) | Arthritis ointment | |
| CN1135108C (en) | A drug for treating joint and soft tissue injuries | |
| CN102258762B (en) | Medicinal composition for diminishing swelling and relieving pain and preparation and use thereof | |
| CN102579614A (en) | External liniment for treating prolapse of lumbar intervertebral disc | |
| CN101843846A (en) | Chinese medicinal ointment for treating skin diseases | |
| CN101912444A (en) | Pharmaceutical composition for quickly setting bones | |
| CN100531780C (en) | Wind-repellent collateral-activating pain-relieving medicine of Herba clemati dis Intricatae | |
| CN101036672A (en) | Rheumatic oil | |
| CN119403561A (en) | Compositions for preventing and treating moisture-related skin damage | |
| Spencer et al. | Efficacy and Safety of Berberex Wound Cleanser on Post-Operative Surgical Incisions | |
| CN103432575B (en) | Composite biological agent for treating neurodermatitis | |
| CN105168415A (en) | Preparation for relieving pain in neck, waist and bones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111228 |